Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Brave Bison lifts outlook after fifth acquisition of 2025

(Sharecast News) - Marketing and tech group Brave Bison on Thursday announced the £6m acquisition of consultancy MTM London, helping it to lift its outlook for the next two years. Following new customer wins including Primark, EQT, Tottenham Hotspur FC, EA Games and Guinness World Records, and with the anticipated contribution from MTM London, Brave Bison said it expects to "exceed current market forecasts for FY25, and increases expectations for FY26" - though no firm financial guidance was given.

MTM provides commercial strategy consulting and audience insights for global tech and media brands like Google, Figma, Samsung and Spotify.

MTM, which generated £8.3m in sales last year, is expected to increase Brave Bison's FY25 pro-forma net revenue to £44m, compared with the current consensus forecast of £36.5m.

The update came as Brave Bisons reported a 19% increase in first-half revenues to £12m and a 6% rise in adjusted EBITDA to £2.3m.

"We have had a busy 2025 so far. Having not made an acquisition for almost two years, we have now announced five transactions in 2025 year to date, improving our competitive position and entering new markets with the acquisition of MiniMBA," said executive chair Oliver Green.

On a statutory basis, pre-tax profits shrank to just £0.1m from £1.2m the year before, though this was largely a result of acquisition, restructuring and integration costs associated with acquisitions.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.